FIVN has produced one of the stranger setups in software this month: the stock is up 45% over the past thirty days, short sellers have added aggressively into the rally, and options traders have rarely been more bullish. The tension between a rebuilding short book and a roaring call-skewed options market is the dominant story this week.
The short interest picture has flipped dramatically since late April. SI % of Free Float was running around 9% through most of April. It climbed through 11% in mid-May, then jumped sharply around May 26 to reach 15.5% of the free float by May 28 — a move of roughly 64% in a single month. That is a meaningful build. Short sellers are clearly not capitulating into the price strength; they are adding to positions as the stock approaches the mid-$20s. FINRA's fortnightly data corroborates the picture, reporting 10.3 million shares short as of the May 15 settlement. Days to cover is a modest 1.9 days, so there is no mechanical squeeze dynamic building yet, but the pace of short accumulation over a week in which the stock gained 7% is striking.
The borrow market, however, is sending a very different signal. Availability is exceptionally loose — shares available to borrow amount to roughly 861% of estimated short interest, meaning there are nearly nine shares available for every one currently borrowed. That ratio sat above 1,000% as recently as mid-May, so there has been some tightening over the past two weeks, but conditions remain far from stressed. Cost to borrow has barely moved, holding around 0.52% annualised — well within the "easy borrow" band. The short book is growing, but the lending market is under no pressure, and new entrants face no friction in establishing positions.
Options positioning is the sharpest bullish signal in the dataset. The put/call ratio of 0.14 on Friday is the lowest in the past 52 weeks — a reading that says call demand is overwhelming put demand by a seven-to-one margin. That sits 1.5 standard deviations below its 20-day average of 0.20, making it the most aggressively call-skewed configuration in the data window. The trend has been consistent since mid-May, when the PCR was still running around 0.24. The directional shift in options has preceded and accompanied the price rally, suggesting active positioning rather than passive hedging.
The Street has been cautiously constructive since the April 30 earnings beat, which delivered a one-day move of +30%. Rosenblatt lifted its target to $29 and UBS to $25 in early May, both maintaining Buy ratings. Barclays also raised its Overweight target to $25. The bears on the Street — DA Davidson and Piper Sandler — also moved their neutral targets up to $22 and $24 respectively, suggesting even the skeptics acknowledged the earnings quality. Needham sits out at a $40 target, though that figure looks like an outlier relative to the consensus mean of $27.81. The current price of $24.35 is already inside several of the recently raised targets, which may explain some of the fresh short activity — the easy post-earnings re-rating has largely been captured. The bull case centres on AI-driven gross margin expansion and accelerating subscription revenues; the bear case focuses on execution risk around AI adoption and macro sensitivity in sales cycles.
The May 20 earnings event in the history data shows a modest -3% one-day move, while April 30's print delivered the +30% surge — a wide reaction range that underlines how event-driven this name has become. With the next earnings date set for August 6, the stock has roughly ten weeks before fundamentals are tested again. Between now and then, the narrative contest is between short sellers rebuilding positions on valuation grounds and call buyers betting the AI revenue inflection story has further to run. Close peers TEAM and ASAN each gained more than 20% this week, reflecting a broader software re-rating, which adds some wind to the bulls' sails but also raises the question of how much sector beta has already been priced in.
The August 6 print is the next hard data point — between now and then, watch whether the short book continues building through $24-$25 resistance and whether the PCR recovers toward its 20-day average or holds at these historically low levels.
See the live data behind this article on ORTEX.
Open FIVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
